Skip to main content
Neurocrine to seek FDA OK for Parkinson's disease therapy

Neurocrine Biosciences plans to submit to the FDA a marketing application for opicapone, which is indicated for Parkinson's disease, in the first half of 2019. The agency has not asked for an additional late-stage study before Neurocrine files.

Full Story: